<DOC>
	<DOCNO>NCT00488722</DOCNO>
	<brief_summary>It find many breast cancer hormone dependent hormonal therapy estrogen suppression ovarian ablation , tamoxifen aromatase inhibitor proven beneficial adjuvant neoadjuvant setting . Zoladex , kind luitinizing hormone release hormone analogue , offer efficient estrogen suppression well . It induce reversible amenorrhea clinical effect similar ovarian ablation . Some study demonstrate efficacy zoladex treat pre perimenopausal hormone dependent breast cancer adjuvant metastatic setting . Few data available Zoladex neoadjuvant treatment breast cancer In department , neoadjuvant CEF regimen general practice , preliminary study design investigate whether add Zoladex neoadjuvant CEF could improve result hormone responsive breast cancer .</brief_summary>
	<brief_title>A Prospective , Single-Arm Study Evaluate Efficacy Safety Zoladex 3.6mg Combined With CEF Chemotherapy Neo-Adjuvant Therapy Hormone Responsive , Premenopausal , Operable Breast Cancer</brief_title>
	<detailed_description>It find many breast cancer hormone dependent hormonal therapy estrogen suppression ovarian ablation , tamoxifen aromatase inhibitor proven beneficial adjuvant neoadjuvant setting . Zoladex , kind luitinizing hormone release hormone analogue , offer efficient estrogen suppression well . It induce reversible amenorrhea clinical effect similar ovarian ablation . Some study demonstrate efficacy zoladex treat pre perimenopausal hormone dependent breast cancer adjuvant metastatic setting . Few data available Zoladex neoadjuvant treatment breast cancer In department , neoadjuvant CEF regimen general practice , preliminary study design investigate whether add Zoladex neoadjuvant CEF could improve result hormone responsive breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>1 . Provision inform consent 2 . Pathological confirmation breast cancer 3 . Tumor stage ( TNM ) : T24bN03M0 4 . ER ( + ) and/or PR ( + ) . 5 . Premenopausal woman . 6 . Age≥40 year 7 . Measurable disease per RECIST criterion 8 . Karnofsky≥70 9 . Labratory criterion : PLT≥100*109/L WBC≥4000/mm3 HGB≥10g/dl ALT AST &lt; 2*ULN 1 . Presence metastatic disease . 2 . Inflammatory breast cancer . 3 . Bilateral breast cancer . 4. previous chemotherapy hormonal therapyfor current breast neoplasm . 5. malignant tumor ( concurrent previous ) . 6 . Pregnant woman . 7 . Hypersensitive drug CEF regimen ingredient Zoladex . 8 . Any severe systemic disease contraindicate chemotherapy .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>To observe biological change concurrent Zoladex CEF neoadjuvant regimen respect ER , PR , cerbB-2 status therapy</keyword>
</DOC>